Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection.

Alessandro Corso1, Marzia Varettoni, Silvia Mangiacavalli

  • 1Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy. a.corso@smatteo.pv.it

Leukemia Research
|December 21, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

European journal of haematology·2026
Same author

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

BMC cancer·2025
Same author

Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols?

Transplant immunology·2025
Same author

Integration of [<sup>18</sup>F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma.

Leukemia·2025
Same author

High-Sensitivity Flow Cytometric Detection of a Small Circulating Population of Nodal T-Follicular Helper Cell Lymphoma Angioimmunoblastic Type Cells.

Journal of medical cases·2025
Same author

An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.

Mediterranean journal of hematology and infectious diseases·2025

Steady-state bone marrow CD34+ cell counts predict peripheral blood progenitor cell yield in patients with hematologic malignancies. Lower bone marrow CD34+ levels indicate a higher risk of inadequate stem cell collection.

Area of Science:

  • Hematology
  • Stem Cell Mobilization
  • Oncology

Background:

  • Peripheral blood progenitor cell (PBPC) mobilization is crucial for hematopoietic stem cell transplantation.
  • Predictive parameters for successful PBPC yield are essential for optimizing collection strategies.

Purpose of the Study:

  • To evaluate the predictive value of steady-state bone marrow (BM) CD34+ cell counts for PBPC yield.
  • To identify clinical and biological variables influencing PBPC mobilization in patients with hematologic malignancies.

Main Methods:

  • Prospective study of 90 patients with multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia undergoing PBPC mobilization.
  • Measurement of bone marrow CD34+ cell counts prior to chemotherapy and growth factor administration.
  • Correlation of BM CD34+ counts with PBPC collection success (target: 4 x 10^6 CD34+ cells/kg).

Related Experiment Videos

Main Results:

  • Bone marrow CD34+ cell count was the only significant predictor of adequate PBPC collection (P=0.04).
  • This association was particularly strong in multiple myeloma patients (P=0.003).
  • A BM CD34+ concentration below 66 cells/µL predicted inadequate collection in multiple myeloma.

Conclusions:

  • Steady-state bone marrow CD34+ cell count is a valuable predictive parameter for PBPC yield.
  • Pre-mobilization BM CD34+ assessment can guide clinical decisions and optimize mobilization strategies.
  • This finding is especially relevant for multiple myeloma patients undergoing stem cell mobilization.